Objectives: We aimed to investigate the recent changes in clinical practice in Korea after the introduction of the national health insurance coverage for polysomnography and positive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) in July 2018. Methods: We assessed the amount, cost, and geographic distribution of healthcare utilization associated with the diagnostic codes of sleep apnea, polysomnography tests, and PAP treatment using the Korea National Health Insurance Database. Furthermore, the specialties of the prescribing physician and the type of health institute were investigated. Results: The number of patients who used health resources under the diagnostic codes of sleep apnea has increased since 2018. In total, 81,016 polysomnography tests were performed from July 2018 to December 2019, and 58,213 patients underwent PAP treatment from July 2018 to March 2020. The total medical cost associated with sleep apnea was 56,517,061 thousand won in 2019. Auto-titrating PAP accounted for 85.1% of all PAP devices prescribed, and the overall adherence rate for PAP was 69.3%. PAP was prescribed most frequently in private clinics (49.9%) and mostly by physicians of ear-nose-throat (66.6%), neurology (18.7%), and psychiatry (10.3%) specializations. PAP was used more frequently by those living in urban areas than by those living in rural areas. Conclusions Recent changes in the national health insurance coverage have resulted in a surge in the healthcare utilization related to OSAS. There was a regional variation in OSAS treatment, suggesting an inequality in the availability of healthcare for OSAS and the need to improve the awareness regarding OSAS.

Objectives: We aimed to investigate the recent changes in clinical practice in Korea after the introduction of the national health insurance coverage for polysomnography and positive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) in July 2018. Methods: We assessed the amount, cost, and geographic distribution of healthcare utilization associated with the diagnostic codes of sleep apnea, polysomnography tests, and PAP treatment using the Korea National Health Insurance Database. Furthermore, the specialties of the prescribing physician and the type of health institute were investigated. Results: The number of patients who used health resources under the diagnostic codes of sleep apnea has increased since 2018. In total, 81,016 polysomnography tests were performed from July 2018 to December 2019, and 58,213 patients underwent PAP treatment from July 2018 to March 2020. The total medical cost associated with sleep apnea was 56,517,061 thousand won in 2019. Auto-titrating PAP accounted for 85.1% of all PAP devices prescribed, and the overall adherence rate for PAP was 69.3%. PAP was prescribed most frequently in private clinics (49.9%) and mostly by physicians of ear-nose-throat (66.6%), neurology (18.7%), and psychiatry (10.3%) specializations. PAP was used more frequently by those living in urban areas than by those living in rural areas. Conclusions Recent changes in the national health insurance coverage have resulted in a surge in the healthcare utilization related to OSAS. There was a regional variation in OSAS treatment, suggesting an inequality in the availability of healthcare for OSAS and the need to improve the awareness regarding OSAS.

Chronic kidney disease is a leading public health problem related to poor quality of life and premature death. As a resource for evidence-informed health policy-making, we evaluated the prevalence of chronic kidney disease using the data of non-institutionalized adults aged ≥ 20 years (n = 15,319) from the Korean National Health and Nutrition Examination Survey in 2011-2013. Chronic kidney disease was defined as a urine albumin-to-creatinine ratio ≥ 30 mg/g or an estimated glomerular filtration rate < 60 mL/min/1.73 m2 using the Chronic Kidney Disease-Epidemiology Collaboration equation. The total prevalence estimate of chronic kidney disease for adults aged ≥ 20 years in Korea was 8.2%. By disease stage, the prevalence of chronic kidney disease was as follows: stage 1, 3.0%; stage 2, 2.7%; stage 3a, 1.9%; stage 3b, 0.4%; and stages 4-5, 0.2%. When grouped into three risk categories according to the 2012 Kidney Disease: Improving Global Outcomes guidelines, the proportions for the moderately increased risk, high risk, and very high risk categories were 6.5%, 1.2%, and 0.5%, respectively. Factors including older age, diabetes, hypertension, cardiovascular disease, body mass indexes of ≥ 25 kg/m2 and < 18.5 kg/m2, and rural residential area were independently associated with chronic kidney disease. Based on this comprehensive analysis, evidence-based screening strategies for chronic kidney disease in the Korean population should be developed to optimize prevention and early intervention of chronic kidney disease and its associated risk factors.
Adult ; Aged ; Albuminuria/complications ; Creatine/urine ; Female ; Glomerular Filtration Rate ; Humans ; Kidney/physiology ; Male ; Middle Aged ; *Nutrition Surveys ; Prevalence ; Renal Insufficiency, Chronic/*epidemiology/pathology ; Republic of Korea/epidemiology ; Risk Factors ; Severity of Illness Index

Background: Cutaneous manifestations are frequently observed in end-stage kidney disease (ESKD) and affect the quality of life (QoL) of patients undergoing maintenance hemodialysis (HD). Even patients undergoing HD who frequently visit hospitals do not receive active dermatological care. The aims of this study were to assess the cutaneous manifestations of patients undergoing HD and investigate changes in their QoL before and after active treatment by dermatologists. Methods: A 12-week prospective study was conducted in two HD centers. Patients in one center received dermatological intervention, while patients in the other center received conservative management by a nephrologist. Patients scored their QoL using the Dermatology Life Quality Index (DLQI) and the Skindex-29 at the start of the study and 12 weeks later. Two matched groups were formed using propensity score matching.Simple and multiple linear regression analyses were used to identify associations between dermatological treatment and the improvement in QoL. Results: In total, 120 patients were included, of whom 65 and 55 were in the intervention and control groups, respectively. Approximately 93.8% of the patients had dermatological manifestations, with pallor and xerosis being the most common. Improvement in QoL, as assessed using the DLQI, was confirmed after 12 weeks in the overall population. However, active intervention by a dermatologist did not significantly improve QoL. Conclusion Patients treated with dermatological intervention by a dermatologist did not achieve greater improvements in QoL than control patients. Therefore, careful assessment of skin issues in patients with ESKD should be undertaken by nephrologists, and the best possible treatment should be administered.

Background: Cutaneous manifestations are frequently observed in end-stage kidney disease (ESKD) and affect the quality of life (QoL) of patients undergoing maintenance hemodialysis (HD). Even patients undergoing HD who frequently visit hospitals do not receive active dermatological care. The aims of this study were to assess the cutaneous manifestations of patients undergoing HD and investigate changes in their QoL before and after active treatment by dermatologists. Methods: A 12-week prospective study was conducted in two HD centers. Patients in one center received dermatological intervention, while patients in the other center received conservative management by a nephrologist. Patients scored their QoL using the Dermatology Life Quality Index (DLQI) and the Skindex-29 at the start of the study and 12 weeks later. Two matched groups were formed using propensity score matching.Simple and multiple linear regression analyses were used to identify associations between dermatological treatment and the improvement in QoL. Results: In total, 120 patients were included, of whom 65 and 55 were in the intervention and control groups, respectively. Approximately 93.8% of the patients had dermatological manifestations, with pallor and xerosis being the most common. Improvement in QoL, as assessed using the DLQI, was confirmed after 12 weeks in the overall population. However, active intervention by a dermatologist did not significantly improve QoL. Conclusion Patients treated with dermatological intervention by a dermatologist did not achieve greater improvements in QoL than control patients. Therefore, careful assessment of skin issues in patients with ESKD should be undertaken by nephrologists, and the best possible treatment should be administered.

Background: Cutaneous manifestations are frequently observed in end-stage kidney disease (ESKD) and affect the quality of life (QoL) of patients undergoing maintenance hemodialysis (HD). Even patients undergoing HD who frequently visit hospitals do not receive active dermatological care. The aims of this study were to assess the cutaneous manifestations of patients undergoing HD and investigate changes in their QoL before and after active treatment by dermatologists. Methods: A 12-week prospective study was conducted in two HD centers. Patients in one center received dermatological intervention, while patients in the other center received conservative management by a nephrologist. Patients scored their QoL using the Dermatology Life Quality Index (DLQI) and the Skindex-29 at the start of the study and 12 weeks later. Two matched groups were formed using propensity score matching.Simple and multiple linear regression analyses were used to identify associations between dermatological treatment and the improvement in QoL. Results: In total, 120 patients were included, of whom 65 and 55 were in the intervention and control groups, respectively. Approximately 93.8% of the patients had dermatological manifestations, with pallor and xerosis being the most common. Improvement in QoL, as assessed using the DLQI, was confirmed after 12 weeks in the overall population. However, active intervention by a dermatologist did not significantly improve QoL. Conclusion Patients treated with dermatological intervention by a dermatologist did not achieve greater improvements in QoL than control patients. Therefore, careful assessment of skin issues in patients with ESKD should be undertaken by nephrologists, and the best possible treatment should be administered.

Background: Cutaneous manifestations are frequently observed in end-stage kidney disease (ESKD) and affect the quality of life (QoL) of patients undergoing maintenance hemodialysis (HD). Even patients undergoing HD who frequently visit hospitals do not receive active dermatological care. The aims of this study were to assess the cutaneous manifestations of patients undergoing HD and investigate changes in their QoL before and after active treatment by dermatologists. Methods: A 12-week prospective study was conducted in two HD centers. Patients in one center received dermatological intervention, while patients in the other center received conservative management by a nephrologist. Patients scored their QoL using the Dermatology Life Quality Index (DLQI) and the Skindex-29 at the start of the study and 12 weeks later. Two matched groups were formed using propensity score matching.Simple and multiple linear regression analyses were used to identify associations between dermatological treatment and the improvement in QoL. Results: In total, 120 patients were included, of whom 65 and 55 were in the intervention and control groups, respectively. Approximately 93.8% of the patients had dermatological manifestations, with pallor and xerosis being the most common. Improvement in QoL, as assessed using the DLQI, was confirmed after 12 weeks in the overall population. However, active intervention by a dermatologist did not significantly improve QoL. Conclusion Patients treated with dermatological intervention by a dermatologist did not achieve greater improvements in QoL than control patients. Therefore, careful assessment of skin issues in patients with ESKD should be undertaken by nephrologists, and the best possible treatment should be administered.

PURPOSE: Constipation is a frequent complaint among dialysis patients. However, factors that contribute to constipation in these patients have not been evaluated rigorously. The aim of study was to assess the prevalence and factors that contribute to constipation in patients with End-Stage Renal Disease (ESRD) undergoing hemodialysis (HD) or peritoneal dialysis (PD). METHODS: Patients undergoing HD or PD for more than six months in the six dialysis centers were asked to complete a self-administered questionnaire that is designed to assess constipation by Rome- III criteria. Beck depression inventory (BDI) were assessed. A total of 146 patients (HD 91, PD 55) completed the study. RESULTS: The prevalence of constipation was 33% in 91 HD patients and 31% in 55 PD patients. Prevalence of constipation was 32% and did not differ by dialysis mode. Older age, unemployed state, high cumulative illness rating scale and high BDI were associated with constipation. In multivariate analysis, BDI was an independent factor associated with constipation. The prevalence of constipation was 18% and 50% for patients with BDI <15 and > or =15, respectively. The odd ratio for constipation in patients with BDI > or =15 was 3.4 (95% CI, 1.4-8.1). CONCLUSION: Careful psychogenic attention must be paid to ESRD patients with constipation.
Constipation ; Depression ; Dialysis ; Humans ; Kidney Failure, Chronic ; Multivariate Analysis ; Peritoneal Dialysis ; Prevalence ; Renal Dialysis ; Surveys and Questionnaires